Gemtuzumab ozogamicin

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Retrieved on: 
Thursday, November 9, 2023
Aplastic anemia, Webcast, Baptist Health South Florida, Transplant, Toxicity, ASH, Acute myeloid leukemia, Leukemia, Patient, Conference, CD33, Pediatric Transplantation, AML, Doctor of Philosophy, Cytokine release syndrome, Pharmaceutical industry, Gemtuzumab ozogamicin, MD

Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).

Key Points: 
  • Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).
  • This data further validates Vor Bio’s approach of using transplant donor cells as CAR-T starting material that are healthy, stem-like, and exactly matched to the patient’s immune system.
  • Vor Bio management will host a live webcast today at 4:30 PM ET.
  • A replay of the webcast will be available via the investor section of the Company’s website at www.vorbio.com approximately two hours after the call’s conclusion.

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 7, 2023
Gene editing, Acute myeloid leukemia, Assistant, Doctor of Philosophy, Flexner Report, Data, Gene, HCT, Hospital, Research and development, Engineering, University, Hospital of the University of Pennsylvania, Patient, Administration, Transplant, DNA, Pediatric Transplantation, Congress, MD, G&A, Research, ASH, Clinical trial, Cytokine release syndrome, General Administration of Sport of China, Editas Medicine, CRS, Principal, Adolescence, IND, Manuscript, Harvard Medical School, Bone marrow, CRISPR, Phenotype, R, CD33, HERE, Toxicity, Associate, AML, Pharmaceutical industry, Dentistry, Vaccine, Nursing, Pediatrics, Gemtuzumab ozogamicin

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $27.6 million, compared to $16.9 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $33.2 million, compared to $23.8 million for the third quarter of 2022.

Global ADC (Antibody Drug Conjugates) Market Research Report 2023-2035: Focus on ADC Linker and ADC Conjugation Technologies - Over 420 ADCs are Currently Being Evaluated - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Conjugation, USFDA, Biomarker, DAR, Seagen, Research, Engineering, ADC, Neoplasm, Zymeworks, Spacecraft, Partnership, Generation, Overalls, Safety, Toxicity, Fine chemical, Vaccine, Linker, Gemtuzumab ozogamicin

The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035.

Key Points: 
  • The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035.
  • The challenges associated with conventional drug products have led to the development of advanced ADC linker and ADC conjugation technologies.
  • The ADC technologies market landscape features an extensive list of over 65 large, mid-sized and small companies that offer more than 95 ADC linker and conjugation technologies.
  • These platforms include linker technologies, linker-payload technologies and antibody conjugation technologies for the development of ADC.

Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
Friday, September 29, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Harvard School of Dental Medicine, Therapy, Cancer, Breast, PI3K, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Enzalutamide, Patient, Yale University, Phosphine, Albert Einstein College of Medicine, Ovarian cancer, Publius Cornelius Arvina, BLA, Pharmaceutical industry, EU, Gemtuzumab ozogamicin, Pfizer

Faeth Therapeutics , a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.

Key Points: 
  • Faeth Therapeutics , a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.
  • Debbie comes to Faeth with years of experience in clinical development and medical affairs, which we look to leverage as we continue the clinical development of our lead assets,” said Anand Parikh, J.D., Chief Executive Officer of Faeth Therapeutics.
  • We aim to empower patients to participate in their care with a science-based, precision approach to nutrition that will enhance their anti-tumor armamentarium,” said Debbie Chirnomas, M.D., M.P.H., Chief Medical Officer of Faeth Therapeutics.
  • “Faeth is a special company with a pioneering mindset based on outstanding science and is uniquely positioned to bring a radically new approach to cancer therapeutics for at-need patients.”

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, August 10, 2023
Research and development, European Hematology Association, Bone marrow, Clinical trial, Passive treatment system, G&A, Toxicity, HCT, Editas Medicine, Trial of the century, Acute myeloid leukemia, Health, U.S. FDA, CAR, AML, CD33, Patient, CGMP, Administration, Engineering, HSC, R, FDA, General Administration of Press and Publication, Pharmaceutical industry, Nursing, Medical device, Dentistry, Vaccine, Fine chemical, Gemtuzumab ozogamicin, IND

VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation

Key Points: 
  • VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation
    CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2023, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2023 were $23.9 million, compared to $15.3 million for the second quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2023 were $8.3 million, compared to $6.5 million for the second quarter of 2022.
  • Net Loss: Net loss for the second quarter of 2023 was $30.0 million, compared to $21.7 million for the second quarter of 2022.

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform

Retrieved on: 
Friday, June 9, 2023
Baptist Health South Florida, European Hematology Association, Conference call, Purpura, Doctor of Philosophy, Nanakaly Hospital for Hematology & Oncology, Acute myeloid leukemia, Congress, CAR, AML, CD33, Patient, EHA, Coronavirus, Webcast, Transplant, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Conference, Food, Pharmaceutical industry, Medical device, Vaccine, MD, Gemtuzumab ozogamicin

“Based on this interim update of five patients treated, we remain confident in the potential of our approach to enable targeted therapies post-transplant.

Key Points: 
  • “Based on this interim update of five patients treated, we remain confident in the potential of our approach to enable targeted therapies post-transplant.
  • Investigator enthusiasm is strong and proposal of patients for enrollment in the study currently exceeds the enrollment stagger.
  • We look forward to sharing further engraftment and hematologic protection data from additional patients treated by year-end,” said Eyal Attar, MD, Vor Bio Chief Medical Officer.
  • Patients 4 and 5 achieved normal neutrophil engraftment and platelet recovery, providing further confidence in the Company’s platform and approach.

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 23, 2023
Haematopoiesis, GMP, Research and development, Siddhartha Mukherjee, Bone marrow, Clinical trial, Passive treatment system, Coronavirus Scientific Advisory Board, Cmax, Doctor of Philosophy, HSCT, Trial of the century, Acute myeloid leukemia, MRD, CAR, AML, Good manufacturing practice, CD33, Patient, Investment, CGMP, Transplant, Administration, Blood, AUC, Biology, TANDEM, HSC, R, Services General Administration and Coordination Department, Government of Sindh, IND, Acute promyelocytic leukemia, Satellite navigation device, Nursing, Vaccine, Dentistry, Cryptocurrency, G&A, MD, Gemtuzumab ozogamicin

In December 2022, Vor Bio announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.

Key Points: 
  • In December 2022, Vor Bio announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.
  • The Company intends to evaluate VCAR33ALLO in combination with trem-cel as a Treatment System, aiming at prolonged remissions or cures following transplant.
  • General & Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2022 were $7.7 million, compared to $5.6 million for the fourth quarter of 2021, and for the year ended December 31, 2022, were $28.9 million, compared to $21.5 million for the year ended December 31, 2021.
  • Net Loss: Net loss for the fourth quarter of 2022 was $23.9 million, compared to $18.3 million for the fourth quarter of 2021, and for the year ended December 31, 2022, was $92.1 million, compared to $68.9 million for the year ended December 31, 2021.

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Retrieved on: 
Thursday, February 16, 2023
AML, AUC, CD33, Cmax, Transplant, Aes, Haematopoiesis, Passive treatment system, MRD, Bone marrow, Patient, AE, Vomiting, Memorial Sloan Kettering Cancer Center, Acute promyelocytic leukemia, Acute myeloid leukemia, Learning, IND, MD, Pharmaceutical industry, Gemtuzumab ozogamicin

In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2.

Key Points: 
  • In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2.
  • A second patient has successfully received a trem-cel transplant and engrafted normally.
  • “We are also encouraged that a second patient successfully received a trem-cel transplant and look forward to learning more as we treat additional patients and dose escalate Mylotarg.
  • The company is moving forward with dose escalation of Mylotarg per the 3+3 dose escalation schema in the protocol.

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Retrieved on: 
Sunday, December 11, 2022
Enzyme, Flow cytometry, WBC, Primate, ASH, AML, Hematocrit, Toxicity, COVID-19, Basophil, Observation, Bilirubin, Form 10-K, Gemstone, NHP, Reticulocyte, Safety, Cancer, Antibody-drug conjugate, CD123, Workforce, Biosimilar, Society, Pandemic, Hematology, Therapy, Diffusion, ADC, Control, Venetoclax, Male, PALO, Patient, Azacitidine, Failure, Bone marrow, Myelocyte, 8-K, Toxic shock syndrome, Drug Quality and Security Act, Survival, Lymphocyte, IND, KSPI, Fine chemical, Pharmaceutical industry, Risk management, Gemtuzumab ozogamicin, Bayer

PALO ALTO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology (ASH) Annual Meeting 2022.

Key Points: 
  • VIP943 combines the unique payload class of kinesin spindle protein inhibitors (KSPi) with a proprietary legumain-cleavable linker.
  • “I am truly excited about the preclinical results for VIP943 and our proprietary payload and linker technology presented at ASH,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • The in vivo AML mouse model results also showed improved efficacy and survival for VIP943 in combination with venetoclax and azacitidine.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Retrieved on: 
Wednesday, December 7, 2022
Gemtuzumab ozogamicin, Cell, HCT, Clinical trial, Leukemia, MTD, Incidence, HLA, Security (finance), Lymphatic system, Webcast, Safety, Stem cell, Engineering, Cancer, CD33, AML1, Acute leukemia, Blood, Cytopenia, AML, Neutropenia, Acute myeloid leukemia, HSPC, Transplant, Toxicity, University Hospitals Cleveland Medical Center, CRISPR, Index (publishing), ANC, Standard of care, Conference call, Patient, Pharmaceutical industry, Conference, Medicine

“These encouraging data represent the first clinical validation of our platform to potentially enable next-generation transplants for patients with blood cancers.

Key Points: 
  • “These encouraging data represent the first clinical validation of our platform to potentially enable next-generation transplants for patients with blood cancers.
  • The patient achieved neutrophil engraftment 10 days post-transplant which was within expectations for CD34-enriched transplants.
  • Transplant with trem-cel is designed to replace standard of care transplants for patients suffering from AML and potentially other blood cancers.
  • The interim data presented in this press release is based on one patient and future results for this patient or additional patients may not produce the same or consistent results.